Efficacy and tolerability of the combination of oxaliplatin, ifosfamide, and epirubicin in treatment of recurrent or platinum-resistant ovarian epithelial cancer patients
- VernacularTitle:IAP方案治疗复发及耐药性卵巢上皮性癌的临床分析
- Author:
Xiaoping LI
;
Heng CUI
;
Jingwei ZHOU
;
Lihui WEI
;
Jianliu WANG
;
Yan ZHAO
;
Yue WANG
;
Shijun WANG
;
Honglan ZHU
;
Li DONG
;
Hong ZHANG
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Organoplatinum compounds;
Epirubicin;
Ifosfamide;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of Obstetrics and Gynecology
2008;43(10):724-727
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and tolerability of the combination of oxaliplatin,ifosfamide and epirubicin(IAP)in treatment of recurrent or platinum-resistant ovarian cancer patients.Methods A total of 25 patients received the combined chemotherapy of ifosfamide(3-4 g/m2),epirubicin(50-60 mg/m2)and oxaliplatin(130 mg/m2).The cycles were repeated every 21 days.The efficacy and toxicity were evaluated in 21 patients who received more than 2 cycles of IAP chemotherapy.Results The overall response rate was 71%,with a complete response in 10(48%),partial response in 5(24%),stable disease in one(5%),and disease progression in 5(24%).The median progression-free and overall survival time were 11(1 to 33)months and 31(1 to 71)months.While overall response rate was 60%in 10 patients with primary platinum resistant,and 88%in 8 patients with secondary platinumresistant.Grade Ⅲ-Ⅳ myelosuppression rate wss 30%.The most common non-hematologic toxicity was perineurotoxicity(38%).Conclusions The combination of oxaliplatin,ifasfamide and epirubicin appears to be effective for recurrent or platinum-resistant ovarian cancer patients as salvage chemotherapy and the toxicity is also tolerable.However,it needs to be evaluated by multiple clinical trials.
